These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31415409)

  • 1. Cost-effectiveness analysis of positron-emission tomography-computed tomography in preoperative staging for nonsmall-cell lung cancer with resected monometastatic disease.
    Zeng X; Peng L; Tan C; Wang Y
    Medicine (Baltimore); 2019 Aug; 98(33):e16843. PubMed ID: 31415409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of
    Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
    BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
    Wang YT; Huang G
    Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
    Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
    Eur J Nucl Med; 2000 Nov; 27(11):1598-609. PubMed ID: 11105815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
    Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
    Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis.
    Burian E; Palla B; Callahan N; Pyka T; Wolff C; von Schacky CE; Schmid A; Froelich MF; Rübenthaler J; Makowski MR; Gassert FG
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3870-3877. PubMed ID: 35606526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
    Scott WJ; Shepherd J; Gambhir SS
    Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
    Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
    Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
    Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
    Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
    Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
    Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
    Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
    Zhai X; Guo Y; Qian X
    Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thoracic staging with
    Schaarschmidt BM; Grueneisen J; Metzenmacher M; Gomez B; Gauler T; Roesel C; Heusch P; Ruhlmann V; Umutlu L; Antoch G; Buchbender C
    Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET-CT in presurgical lymph node staging in non-small cell lung cancer: the importance of false-negative and false-positive findings.
    Bustos García de Castro A; Ferreirós Domínguez J; Delgado Bolton R; Fernández Pérez C; Cabeza Martínez B; García García-Esquinas M; Carreras Delgado JL
    Radiologia; 2017; 59(2):147-158. PubMed ID: 28238444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
    Li C; Tian Y; Shen Y; Wen B; He Y
    AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
    [No Abstract]   [Full Text] [Related]  

  • 20. The optimal timing of FDG-PET/CT in non-small cell lung cancer diagnosis and staging in an Australian centre.
    Johnson A; Norman R; Piccolo F; Manners D
    BMC Pulm Med; 2021 Jul; 21(1):209. PubMed ID: 34210303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.